Current Cardiology Reports

, Volume 3, Issue 5, pp 416–423 | Cite as

Pathophysiology and treatment of the dyslipidemia of insulin resistance

  • Gregory Cohn
  • Gerardo Valdes
  • David M. Capuzzi


Insulin resistance, and the compensatory hyperinsulinemia that results, has been linked to a host of defects including glucose intolerance, diabetes, hypertension, dyslipidemia, endothelial dysfunction, impaired fibrinolysis, and subclinical inflammation. Patients with this metabolic syndrome have a markedly increased risk for the development of atherothrombotic cardiovascular disease. The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol. Management of this dyslipidemia typically involves a dual approach. Lifestyle modification is an essential component of any successful treatment plan, but alone is usually insufficient to correct these lipoprotein abnormalities. Medications that diminish insulin resistance and directly alter lipoproteins are also necessary in the majority of cases. Combinations of therapeutic agents are often required to optimize attainment of treatment goals.


Insulin Resistance Metformin Gemfibrozil Orlistat Insulin Resistance Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998, 339:229–234.PubMedCrossRefGoogle Scholar
  2. 2.
    Dagogo-Jack S, Santiago JV: Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Int Med 1997, 103:1802–1817.CrossRefGoogle Scholar
  3. 3.
    Eschwege E, Richard JL, Thibult N, et al.: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris prospective study, ten years later. Horm Metab Res 1985, 15(suppl): 41–46.Google Scholar
  4. 4.
    Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. New Engl J Med 1996, 334:952–957.PubMedCrossRefGoogle Scholar
  5. 5.
    Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997, 103:152–162. An excellent summary of the relationships between IR and the major cardiovascular risk factors.PubMedCrossRefGoogle Scholar
  6. 6.
    Reaven GM: Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991, 121:1283–1288.PubMedCrossRefGoogle Scholar
  7. 7.
    Rett K: The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999, 1(suppl 1):8–6.CrossRefGoogle Scholar
  8. 8.
    Festa A, D’Agostino, Jr. R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42–47.PubMedGoogle Scholar
  9. 9.
    Mokdad AH, Serdula Mk, Dietz WH, et al.: The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999, 282:1519–1522.PubMedCrossRefGoogle Scholar
  10. 10.
    Must A, Spradano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529.PubMedCrossRefGoogle Scholar
  11. 11.
    Kwiterovich, Jr. PO: The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000, 86(12 Suppl 1):5–10. A concise review of both normal and abnormal lipoprotein metabolism.CrossRefGoogle Scholar
  12. 12.
    Goldberg RB, Capuzzi D: Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med 2001, 21:147–171.PubMedGoogle Scholar
  13. 13.
    Superko HR: Small, dense low-density lipoprotein subclass pattern B: issues for the clinician. Curr Atheroscler Rep 1999, 1:50–57. A great review of small, dense LDL-C by one of the leaders in the field.PubMedCrossRefGoogle Scholar
  14. 14.
    O’Keefe, Jr. JH, Miles JM, Harris WH, et al.: Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999, 74:171–180. Another outstanding review of the links between IR and CVD. Drug therapy is reviewed in some detail as well.PubMedCrossRefGoogle Scholar
  15. 15.
    Knopp RH: Current concepts in dietary therapy for dyslipidemia. In Mediguide to Heart Diseases. Edited by AM Gotto, Jr. New York: Lawrence DellaCorte; 2000, 3:1–8. A succinct, evidence-based summary of the effects of various diets on dyslipidemia.Google Scholar
  16. 16.
    O’Keefe, Jr. JH, Harris WS: From inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000, 75:607–614.PubMedGoogle Scholar
  17. 17.
    Shikany JM, White Jr. GL: Dietary guidelines for chronic disease prevention. South Med J 2000, 93:1138–1151.PubMedGoogle Scholar
  18. 18.
    Lynch J, Helmrich SP, Lakka TA, et al.: Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Int Med 1996, 156:1307–1314.CrossRefGoogle Scholar
  19. 19.
    Henry RR: Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Int Med 1996, 124(suppl 1):97–103.PubMedGoogle Scholar
  20. 20.
    Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Arch Int Med 1998, 158:1855–1867.Google Scholar
  21. 21.
    Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242.PubMedCrossRefGoogle Scholar
  22. 22.
    Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Int Med 2000, 160:1321–1326.CrossRefGoogle Scholar
  23. 23.
    Lindgarde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study. J Int Med 2000, 248:245–254.CrossRefGoogle Scholar
  24. 24.
    Grosskopf I, Ringel Y, Charach G, et al.: Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care 1997, 20:1598–1602.PubMedCrossRefGoogle Scholar
  25. 25.
    Charles MA, Morange P, Eschwege E, et al.: Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO 1 Study. Diabetes Care 1998, 21:1967–1972.PubMedCrossRefGoogle Scholar
  26. 26.
    Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. Circulation 2001, 37:1344–1350.Google Scholar
  27. 27.
    Defronzo RA: Treatment of type 2 diabetes mellitus: a sound approach based upon its pathophysiology. Lawrenceville: Academy of Medicine of New Jersey; 2001:21–23.Google Scholar
  28. 28.
    Parulkar AA, Pendergrass ML, Granda-Ayala R, et al.: Nonhypoglycemic effects of thiazolidinedones. Ann Int Med 2001, 134:61–71. Explores the many benefits of this class of medication on IR beyond improved glucose control.PubMedGoogle Scholar
  29. 29.
    Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153. A landmark study in CVD prevention whose implications will be debated well into the future.CrossRefGoogle Scholar
  30. 30.
    Hansson L, Lindholm LH, Niskanenn L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) Randomized Trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  31. 31.
    Baron AD: Vascular reactivity. Amer J Cardiol 1999, 84:25J-27J.PubMedCrossRefGoogle Scholar
  32. 32.
    Petrie JR, Ueda S, Webb DJ, et al.: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996, 93:1331–1333.PubMedGoogle Scholar
  33. 33.
    Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649–1652.PubMedCrossRefGoogle Scholar
  34. 34.
    Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Int Med 1999, 159:2661–2667.CrossRefGoogle Scholar
  35. 35.
    Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.PubMedGoogle Scholar
  36. 36.
    Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498–511.PubMedCrossRefGoogle Scholar
  37. 37.
    Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37–45.PubMedGoogle Scholar
  38. 38.
    Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418.PubMedCrossRefGoogle Scholar
  39. 39.
    Effect of Fenofibrate on Progression of Coronary Artery Disease in Type 2 Diabetes: The Diabetes Atherosclerosis Intervention Study. Lancet 2001, 357:905–910.Google Scholar
  40. 40.
    Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM: Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2000, 2:64–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JACC 1986, 8:1245–1255.PubMedGoogle Scholar
  42. 42.
    Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418.PubMedCrossRefGoogle Scholar
  43. 43.
    Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. the ADMIT Study: a randomized trial. JAMA 2000, 284:1263–1270.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Gregory Cohn
    • 1
  • Gerardo Valdes
  • David M. Capuzzi
  1. 1.Cleveland Clinic FloridaWestonUSA

Personalised recommendations